dostęp otwarty

Tom 7, Nr 4 (2016)
Artykuł przeglądowy
Opublikowany online: 2017-04-07
Pobierz cytowanie

Molekularna patogeneza przewlekłej białaczki limfocytowej

Emilia Białopiorowicz, Przemysław Juszczyński
DOI: 10.5603/Hem.2016.0026
·
Hematologia 2016;7(4):273-286.

dostęp otwarty

Tom 7, Nr 4 (2016)
PRACE POGLĄDOWE
Opublikowany online: 2017-04-07

Streszczenie

Przewlekła białaczka limfocytowa (CLL) to najczęstszy typ białaczki u osób dorosłych, charaktery­zujący się nagromadzeniem dojrzałych limfocytów B we krwi obwodowej, szpiku kostnym i tkan­kach limfatycznych. Kliniczny przebieg CLL jest zróżnicowany i obejmuje spektrum przypadków od takich o powolnym, wieloletnim przebiegu po przypadki agresywne, w których nowotwór rozwija się gwałtownie i kończy zgonem chorego w krótkim czasie. Zastosowanie nowoczesnych technik biologii molekularnej ujawniło znaczną heterogenność genetyczną i epigenetyczną wśród chorych na CLL oraz pozwoliło wytypować mutacje somatyczne o istotnym znaczeniu rokowniczym. Za­równo genom, jak i epigenom CLL podlegają dynamicznym zmianom w trakcie przebiegu choroby wskutek ewolucji klonalnej, która prowadzi do selekcji i ekspansji klonów komórek białaczkowych o najwyższym potencjale dostosowawczym. W niniejszej pracy omówiono najważniejsze aspekty molekularnej patogenezy CLL, w tym rolę zaburzeń genetycznych i epigenetycznych, sygnału od receptora B-komórkowego oraz wpływ mikrośrodowiska. Postępy w zakresie zrozumienia biologii CLL przyczynią się do opracowania lepszego systemu prognozowania oraz umożliwią bardziej spersonalizowane leczenie tej choroby w przyszłości.

Streszczenie

Przewlekła białaczka limfocytowa (CLL) to najczęstszy typ białaczki u osób dorosłych, charaktery­zujący się nagromadzeniem dojrzałych limfocytów B we krwi obwodowej, szpiku kostnym i tkan­kach limfatycznych. Kliniczny przebieg CLL jest zróżnicowany i obejmuje spektrum przypadków od takich o powolnym, wieloletnim przebiegu po przypadki agresywne, w których nowotwór rozwija się gwałtownie i kończy zgonem chorego w krótkim czasie. Zastosowanie nowoczesnych technik biologii molekularnej ujawniło znaczną heterogenność genetyczną i epigenetyczną wśród chorych na CLL oraz pozwoliło wytypować mutacje somatyczne o istotnym znaczeniu rokowniczym. Za­równo genom, jak i epigenom CLL podlegają dynamicznym zmianom w trakcie przebiegu choroby wskutek ewolucji klonalnej, która prowadzi do selekcji i ekspansji klonów komórek białaczkowych o najwyższym potencjale dostosowawczym. W niniejszej pracy omówiono najważniejsze aspekty molekularnej patogenezy CLL, w tym rolę zaburzeń genetycznych i epigenetycznych, sygnału od receptora B-komórkowego oraz wpływ mikrośrodowiska. Postępy w zakresie zrozumienia biologii CLL przyczynią się do opracowania lepszego systemu prognozowania oraz umożliwią bardziej spersonalizowane leczenie tej choroby w przyszłości.

Pobierz cytowanie

Słowa kluczowe

przewlekła białaczka limfocytowa, patogeneza, genom, epigenom, mikrośrodowisko, architektura klonalna, ewolucja klonalna

Informacje o artykule
Tytuł

Molekularna patogeneza przewlekłej białaczki limfocytowej

Czasopismo

Hematologia

Numer

Tom 7, Nr 4 (2016)

Typ artykułu

Artykuł przeglądowy

Strony

273-286

Data publikacji on-line

2017-04-07

DOI

10.5603/Hem.2016.0026

Rekord bibliograficzny

Hematologia 2016;7(4):273-286.

Słowa kluczowe

przewlekła białaczka limfocytowa
patogeneza
genom
epigenom
mikrośrodowisko
architektura klonalna
ewolucja klonalna

Autorzy

Emilia Białopiorowicz
Przemysław Juszczyński

Referencje (113)
  1. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007; 139(5): 809–819.
  2. Richardson DB, Wing S, Schroeder J, et al. Ionizing radiation and chronic lymphocytic leukemia. Environ Health Perspect. 2005; 113(1): 1–5.
  3. Goldin LR, Pfeiffer RM, Li X, et al. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004; 104(6): 1850–1854.
  4. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015; 126(4): 454–462.
  5. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90(5): 446–460.
  6. Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. Semin Diagn Pathol. 2011; 28(2): 161–166.
  7. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005; 115(3): 755–764.
  8. Parikh SA, Shanafelt TD. Prognostic factors and risk stratification in chronic lymphocytic leukemia. Semin Oncol. 2016; 43(2): 233–240.
  9. Zenz T, Mertens D, Küppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010; 10(1): 37–50.
  10. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994; 8(10): 1640–1645.
  11. Seiffert M, Schulz A, Ohl S, et al. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood. 2010; 116(20): 4223–4230.
  12. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012; 44(11): 1236–1242.
  13. Oakes CC, Seifert M, Assenov Y, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016; 48(3): 253–264.
  14. Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011; 20(2): 246–259.
  15. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014; 4(9): 1088–1101.
  16. Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015; 94(3): 193–205.
  17. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011; 117(2): 563–574.
  18. Burger J, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends in Immunology. 2013; 34(12): 592–601.
  19. Vardi A, Agathangelidis A, Sutton LA, et al. Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. Cancer Res. 2014; 74(16): 4211–4216.
  20. Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood. 2008; 112(13): 5122–5129.
  21. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008; 111(7): 3838–3848.
  22. Kostareli E, Gounari M, Janus A, et al. Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia. 2012; 26(5): 1127–1131.
  23. Duhren-von Minden M, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukemia is driven by antigen-independent cell-autonomous signaling. 2012; 489: 309–312.
  24. Ten Hacken H, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment. 2016; 1863: 401–413.
  25. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013; 339(6127): 1546–1558.
  26. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26): 1910–1916.
  27. Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007; 21(12): 2442–2451.
  28. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574): 525–530.
  29. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002; 99(24): 15524–15529.
  30. Palamarchuk A, Efanov A, Nazaryan N, et al. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010; 115(19): 3916–3922.
  31. Ouillette P, Collins R, Shakhan S, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res. 2011; 17(21): 6778–6790.
  32. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013; 14(4): 197–210.
  33. Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol. 2012; 30(36): 4524–4532.
  34. Stankovic T, Skowronska A. The role ofATMmutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leukemia & Lymphoma. 2013; 55(6): 1227–1239.
  35. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012; 119(12): 2854–2862.
  36. Gorniak P, Budziszewska B, Pula B, et al. Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease. Leuk Lymphoma. 2016; 57(6): 1471–1473.
  37. Strati P, Abruzzo LV, Wierda WG, et al. Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2015; 15(7): 420–427.
  38. Chigrinova E, Rinaldi A, Kwee I, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013; 122(15): 2673–2682.
  39. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014; 14(5): 359–370.
  40. Yu L, Kim HT, Kasar SN, et al. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clin Cancer Res. 2017; 23(3): 735–745.
  41. Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009; 114(26): 5307–5314.
  42. Pospisilova S, Gonzalez D, Malcikova J, et al. European Research Initiative on CLL (ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012; 26(7): 1458–1461.
  43. Lee HJ, Gallardo M, Ma H, et al. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J. 2016; 6: e434.
  44. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11): 997–1007.
  45. Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016; 127(25): 3215–3224.
  46. Bialopiotrowicz E, Gorniak P, Pula B, et al. Microenvironment-induced expression of PIM kinases supports chronic lymphocytic leukemia cells survival and promotes CXCR4-mTOR pathway dependent migration. Blood. 2016; 128: 3239.
  47. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016; 16(3): 145–162.
  48. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365(26): 2497–2506.
  49. Ramsay AJ, Rodríguez D, Villamor N, et al. Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia. Leukemia. 2013; 27(7): 1600–1603.
  50. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica. 2012; 97(3): 437–441.
  51. Bilous NI, Abramenko IV, Chumak AA, et al. Detection of NOTCH1 c.7541_7542delCT mutation in chronic lymphocytic leukemia using conventional and real-time polymerase chain reaction. Exp Oncol. 2016; 38(2): 112–116.
  52. Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015; 526(7574): 519–524.
  53. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011; 44(1): 47–52.
  54. Golas MM, Sander B, Will CL, et al. Molecular architecture of the multiprotein splicing factor SF3b. Science. 2003; 300(5621): 980–984.
  55. Rawlings DJ, Schwartz MA, Jackson SW, et al. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 2012; 12(4): 282–294.
  56. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354): 101–105.
  57. Mansouri L, Sutton LA, Ljungström V, et al. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015; 212(6): 833–843.
  58. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121(8): 1403–1412.
  59. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014; 28(1): 108–117.
  60. Baliakas P, Hadzidimitriou A, Sutton LA, et al. European Research Initiative on CLL (ERIC). Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015; 29(2): 329–336.
  61. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281–297.
  62. Baer C, Claus R, Frenzel LP, et al. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res. 2012; 72(15): 3775–3785.
  63. Wu H, Zhang Yi. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell. 2014; 156(1-2): 45–68.
  64. Kanduri M, Cahill N, Göransson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010; 115(2): 296–305.
  65. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2011; 117(6): 1781–1791.
  66. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26): 2477–2487.
  67. Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009; 360(7): 659–667.
  68. Rawstron AC, Bennett FL, O'Connor SJM, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6): 575–583.
  69. Ojha J, Secreto C, Rabe K, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia. 2014; 28(12): 2395–2398.
  70. Guièze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015; 126(4): 445–453.
  71. Messina M, Del Giudice I, Khiabanian H, et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood. 2014; 123(15): 2378–2388.
  72. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013; 210(11): 2273–2288.
  73. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152(4): 714–726.
  74. Wang J, Khiabanian H, Rossi D, et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. Elife. 2014; 3: e02869.
  75. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014; 123(14): 2139–2147.
  76. Oakes CC, Claus R, Gu L, et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014; 4(3): 348–361.
  77. Landau DA, Clement K, Ziller MJ, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014; 26(6): 813–825.
  78. Panayiotidis P, Jones D, Ganeshaguru K, et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996; 92(1): 97–103.
  79. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000; 96(8): 2655–2663.
  80. Jia Li, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014; 123(11): 1709–1719.
  81. Binder M, Léchenne B, Ummanni R, et al. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS One. 2010; 5(12): e15992.
  82. Seiffert M, Schulz A, Ohl S, et al. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood. 2010; 116(20): 4223–4230.
  83. Purroy N, Abrisqueta P, Carabia J, et al. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015; 6(10): 7632–7643.
  84. Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007; 110(12): 4012–4021.
  85. Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008; 111(5): 2685–2692.
  86. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6): 1840–1847.
  87. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18): 1764–1775.
  88. Marquez ME, Hernández-Uzcátegui O, Cornejo A, et al. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL. Br J Haematol. 2015; 169(2): 211–218.
  89. Ghosh AK, Secreto C, Boysen J, et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011; 117(6): 1928–1937.
  90. Cols M, Barra CM, He B, et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol. 2012; 188(12): 6071–6083.
  91. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002; 100(5): 1795–1801.
  92. Granziero L, Circosta P, Scielzo C, et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood. 2003; 101(5): 1962–1969.
  93. Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013; 98(6): 953–963.
  94. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008; 118(7): 2427–2437.
  95. Ramsay AG, Evans R, Kiaii S, et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013; 121(14): 2704–2714.
  96. Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005; 19(10): 1788–1793.
  97. Zaleska J, Skorka K, Zajac M, et al. Specific cytotoxic T-cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells. Br J Haematol. 2016; 174(4): 582–590.
  98. Bürkle A, Niedermeier M, Schmitt-Gräff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007; 110(9): 3316–3325.
  99. Bleul CC. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). Journal of Experimental Medicine. 1996; 184(3): 1101–1109.
  100. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000; 96(8): 2655–2663.
  101. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005; 106(5): 1824–1830.
  102. Möhle R, Failenschmid C, Bautz F, et al. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia. 1999; 13(12): 1954–1959.
  103. Decker S, Finter J, Forde AJ, et al. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Mol Cancer Ther. 2014; 13(5): 1231–1245.
  104. Mittal AK, Chaturvedi NK, Rai KJ, et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med. 2014; 20: 290–301.
  105. Fecteau JF, Corral LG, Ghia EM, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014; 124(10): 1637–1644.
  106. Schulz A, Dürr C, Zenz T, et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood. 2013; 121(13): 2503–2511.
  107. Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int. 2014; 2014: 265840.
  108. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008; 14(14): 4650–4657.
  109. Chen SS, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016; 30(4): 833–843.
  110. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119(5): 1182–1189.
  111. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009; 23(1): 43–52.
  112. Stamatopoulos B, Meuleman N, De Bruyn C, et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica. 2012; 97(4): 608–615.
  113. Hoellenriegel J, Zboralski D, Maasch C, et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014; 123(7): 1032–1039.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl